CEO Today - February 2023

20 Please tell us your story. I’m the Chief Executive Officer of Kuros Biosciences AG (SIX: KURN) and I also hold the position of Professor of Biomaterials at Queen Mary University of London, UK (since 2004).Until recently, I was Professor of Regenerative Medicine and Entrepreneurship at Twente University, The Netherlands (from 2011 2019). I’m the founder and CEO of Xpand Biotechnology B.V. that was acquired by Kuros Biosciences AG early 2017 and prior to this was involved with Progentix Orthobiology BV (founder and CEO) that was acquired by NuVasive Inc., Scinus Cell Expansion BV (founder) and IsoTis Orthobiologics NV. I have more than 33 years of experience in academia and the life science industry and have brought several technologies to the clinic. I’ve authored close to 200 peer-reviewed publications and invented 35 patents and patent families. I’m a scientific editor of the world’s first open-access journal, European Cells and Materials, and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. I received my PhD Cum Laude from Leiden University in 1993. Can you please introduce us to Kuros Biosciences? Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland, and the Netherlands, Kuros is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOs, is a unique synthetic bone graft that has already been used successfully across three continents and in more than 10,000 spinal fusion surgeries. The next candidate in the Kuros pipeline is “Kuros Biosciences is a fastgrowing leader in the development of spinal fusion biologics that ease the burden of back pain.” THE CEO INTERVIEW

RkJQdWJsaXNoZXIy Mjk3Mzkz